REL and ovarian cancer: In the present study, we observed for the first time that NF-κB, c-Rel, and ELK1 bind to their respective recognition sites in the putative promoter region of miR-134 and suppress its expression in paclitaxel-resistant SKOV3-TR30 ovarian cancer cells.